Global Protein Therapeutics Market

Protein Therapeutics Market Size, Share, Growth Analysis, By Product Type(Monoclonal Antibodies, Insulin, Vaccines, Growth Hormones), By Application(Oncology, Hematology, Immunology, Metabolic Disorders), By Therapeutic Area(Cancer, Diabetes, Infectious Diseases, Autoimmune Disorders), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2238 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 99 | Figures: 76

Protein Therapeutics Market News

  • In October 2023, Lumakras is the latest protein-based drug approved by the U.S. FDA for treating non-small cell lung cancer. The path-breaking monoclonal antibody is therefore well positioned in terms of targeted therapy for cancer. Thus, this demonstrates Amgen's commitment to continuing to expand its oncology pipeline. 
  • In July 2023, Roche launched this novel protein therapy with Hemlibra, specifically for hemophilia A patients. The therapy acts as a substitute for the deficient clotting factor and will yield better results as compared to the older treatment options available. This approval reaffirms Roche's leadership in the field of innovating hematology. 
  • In June 2023, A new invention from Johnson & Johnson is a protein-based vaccine for the Respiratory Syncytial Virus (RSV). This protein therapeutics approach is geared to help with fewer hospitalizations and severe symptoms among the most vulnerable populations. The vaccine is just the latest example of the continued effort expected from Johnson & Johnson in innovating targeted biologics for emerging infectious diseases.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Protein Therapeutics Market size was valued at USD 6.57 billion in 2022 and is poised to grow from USD 6.96 billion in 2023 to USD 11.10 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).

The global protein therapeutics market is highly competitive, with several prominent players driving innovation and market growth. Companies in this space include many other marquee names like Amgen, Roche, Novartis, Johnson & Johnson, and AbbVie, all involved in cutting-edge development of biologics, monoclonal antibodies, and enzyme therapy products. These companies spend enormous amounts of money on research and development to enhance their portfolios to meet the future demand for increased therapeutic targeting in oncology, autoimmune or metabolic disorders applications.  'Amgen Inc. (US)', 'AbbVie Inc. (US)', 'Roche Diagnostics (Switzerland)', 'Eli Lilly and Company (US)', 'Johnson & Johnson (US)', 'Pfizer Inc. (US)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Novo Nordisk A/S (Denmark)', 'Merck & Co., Inc. (US)', 'Celgene Corporation (US)', 'GlaxoSmithKline PLC (UK)', 'Gilead Sciences, Inc. (US)', 'Biogen Inc. (US)', 'AstraZeneca PLC (UK)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Abbott Laboratories (US)', 'Bayer AG (Germany)', 'Alexion Pharmaceuticals Inc. (US)', 'Novartis AG (Switzerland)', 'Sanofi (France)'

Rising Demand for Personalized Medicine: The growing shift toward personalized medicine is driving the global protein therapeutics market trends, with therapies tailored to individual genetic profiles. This trend-potentiating treatment efficacy with least effects has increased demand and needs of advanced drugs, particularly for cancers and other autoimmune diseases, to push the application of targeted biologics and protein therapies further. 

North America dominates the global protein therapeutics market due to its advanced healthcare infrastructure, robust biotechnology sector, and significant investment in research and development. Innovation-based protein therapy development and approval, commercialization mostly occurs in the U.S. This is complemented by the strong regulatory frameworks and an outsize presence of most pharmaceutical companies in the country. Chronic diseases like cancer and metabolic disorders are on the rise. Healthcare spending continues growing, and there is an increase in personalized medicine, which propels demand for protein therapeutics. Major thrusts for the region, particularly North America, are new medical research and robust healthcare reimbursement policies that keep defining leadership in the market. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Protein Therapeutics Market

Report ID: SQMIG35H2238

$5,300
BUY NOW GET FREE SAMPLE